Safety of Ustekinumab and Vedolizumab During Pregnancy—Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study

202245 citationsJournal Article

Authors

Katarína Mitrová · Iscare I.V.F

Barbora Pipek · University Hospital Olomouc

Martin Bortlík · Institute of Pharmacology

Luděk Bouchner · Charles University

Jan Březina · Institute of Clinical and Experimental Medicine

Tomáš Douda · Charles University

Tomas Drasar ·

Abstract

Use of ustekinumab and vedolizumab in pregnancy seems to be safe, with favuorable pregnancy and postnatal infant outcomes. Placental transfer differed between these two drugs, with ustekinumab having similar and vedolizumab having inverse infant-to-maternal ratio of drug levels compared with anti-TNF preparations.

Topics & Keywords

Pregnancy and Medication Impact Reproductive System and Pregnancy Eosinophilic Esophagitis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Crohn s and Colitis

Volume 16, Issue 12, pp. 1808-1815

DOI: 10.1093/ecco-jcc/jjac086

Field-Weighted Citation Impact: 8.58